Summary

The global AAV Vector-Based Gene Therapy Drugs market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.
AAV vector-based gene therapy drugs are a class of therapeutic agents used in the treatment of genetic disorders and certain diseases These drugs utilize AAV vectors, which are small, non-enveloped viruses that have a low pathogenic profile and are capable of delivering genetic material into host cells. The genetic material, which be a functional gene or a therapeutic gene, is inserted into the AAV vector and then introduced into the patient's cells, where it is intended to correct genetic mutations or produce therapeutic proteins. AAV vector-based gene therapy has shown promising results in clinical trials for conditions such as Leber congenital amaurosis, spinal muscular atrophy, and certain retinal diseases.
In 2025, the North America AAV Vector-Based Gene Therapy Drugs market was US$ million, while the Europe market stood at US$ million. North America accounted for % of the global market in 2025 and Europe for %. Europe’s share is expected to reach % by 2032, corresponding to a CAGR of % over the analysis period.
The global key players of AAV Vector-Based Gene Therapy Drugs include uniQure, Spark Therapeutics, AveXis (Novartis), PTC Therapeutics, BioMarin, Sarepta Therapeutics, Roche, Pfizer, among others. In 2025, the top five players accounted for approximately % of global market revenue.
In terms of revenue, the top three players in North America accounted for about % of the market in 2025, while the top three in Europe held nearly %.
The global AAV Vector-Based Gene Therapy Drugs market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Application for 2021-2032.
Market Segmentation
By Company:
uniQure
Spark Therapeutics
AveXis (Novartis)
PTC Therapeutics
BioMarin
Sarepta Therapeutics
Roche
Pfizer
Segment by Type
AAV2 Vector
AAV5 Vector
Others
Segment by Application
Hospital
Diagnostic and Testing Laboratories
Academic and Research Organizations
Others
By Region
Macro-Region
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local Markets
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
(Additional regions can be customized based on client needs.)
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term)
Chapter 2: Quantitative analysis of AAV Vector-Based Gene Therapy Drugs market size and growth potential at global, regional, and country levels
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus)
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities
Chapter 6: Regional revenue breakdown by company, type, application and customer
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the AAV Vector-Based Gene Therapy Drugs value chain, addressing:
- Market entry risks/opportunities by region
- Product mix optimization based on local practices
- Competitor tactics in fragmented vs. consolidated markets

ページTOPに戻る

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size and Growth by Type: 2021 vs 2025 vs 2032
1.2.2 AAV2 Vector
1.2.3 AAV5 Vector
1.2.4 Others
1.3 Market by Application
1.3.1 Global Market Share by Application: 2021 vs 2025 vs 2032
1.3.2 Hospital
1.3.3 Diagnostic and Testing Laboratories
1.3.4 Academic and Research Organizations
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered

2 Global Growth Trends
2.1 Global AAV Vector-Based Gene Therapy Drugs Market Perspective (2021-2032)
2.2 Global Market Size by Region: 2021 vs 2025 vs 2032
2.3 Global AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Region (2021-2026)
2.4 Global AAV Vector-Based Gene Therapy Drugs Revenue Forecast by Region (2027-2032)
2.5 Major Regions and Emerging Markets Analysis
2.5.1 North America AAV Vector-Based Gene Therapy Drugs Market Size and Prospective (2021-2032)
2.5.2 Europe AAV Vector-Based Gene Therapy Drugs Market Size and Prospective (2021-2032)
2.5.3 Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Size and Prospective (2021-2032)
2.5.4 Latin America AAV Vector-Based Gene Therapy Drugs Market Size and Prospective (2021-2032)
2.5.5 Middle East & Africa AAV Vector-Based Gene Therapy Drugs Market Size and Prospective (2021-2032)

3 Breakdown Data by Type
3.1 Global AAV Vector-Based Gene Therapy Drugs Historical Market Size by Type (2021-2026)
3.2 Global AAV Vector-Based Gene Therapy Drugs Forecasted Market Size by Type (2027-2032)
3.3 Representative Players for Different Types of AAV Vector-Based Gene Therapy Drugs

4 Breakdown Data by Application
4.1 Global AAV Vector-Based Gene Therapy Drugs Historical Market Size by Application (2021-2026)
4.2 Global AAV Vector-Based Gene Therapy Drugs Forecasted Market Size by Application (2027-2032)
4.3 New Sources of Growth in AAV Vector-Based Gene Therapy Drugs Applications

5 Competitive Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top AAV Vector-Based Gene Therapy Drugs Players by Revenue (2021-2026)
5.1.2 Global AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Players (2021-2026)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by AAV Vector-Based Gene Therapy Drugs Revenue
5.4 Global AAV Vector-Based Gene Therapy Drugs Market Concentration Analysis
5.4.1 Global AAV Vector-Based Gene Therapy Drugs Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by AAV Vector-Based Gene Therapy Drugs Revenue in 2025
5.5 Global Key Players of AAV Vector-Based Gene Therapy Drugs Head Offices and Areas Served
5.6 Global Key Players of AAV Vector-Based Gene Therapy Drugs, Product and Application
5.7 Global Key Players of AAV Vector-Based Gene Therapy Drugs, Date of Entry into This Industry
5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis
6.1 North America Market: Players, Segments, Downstream and Major Customers
6.1.1 North America AAV Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026)
6.1.2 North America Market Size by Type
6.1.2.1 North America AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026)
6.1.2.2 North America AAV Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
6.1.3 North America Market Size by Application
6.1.3.1 North America AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026)
6.1.3.2 North America AAV Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
6.1.4 North America AAV Vector-Based Gene Therapy Drugs Major Customers
6.1.5 North America Market Trends and Opportunities
6.2 Europe Market: Players, Segments, Downstream and Major Customers
6.2.1 Europe AAV Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026)
6.2.2.2 Europe AAV Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
6.2.3 Europe Market Size by Application
6.2.3.1 Europe AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026)
6.2.3.2 Europe AAV Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
6.2.4 Europe AAV Vector-Based Gene Therapy Drugs Major Customers
6.2.5 Europe Market Trends and Opportunities
6.3 Asia-Pacific Market: Players, Segments, Downstream and Major Customers
6.3.1 Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026)
6.3.2.2 Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
6.3.3 Asia-Pacific Market Size by Application
6.3.3.1 Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026)
6.3.3.2 Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
6.3.4 Asia-Pacific AAV Vector-Based Gene Therapy Drugs Major Customers
6.3.5 Asia-Pacific Market Trends and Opportunities
6.4 Latin America Market: Players, Segments, Downstream and Major Customers
6.4.1 Latin America AAV Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026)
6.4.2 Latin America Market Size by Type
6.4.2.1 Latin America AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026)
6.4.2.2 Latin America AAV Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
6.4.3 Latin America Market Size by Application
6.4.3.1 Latin America AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026)
6.4.3.2 Latin America AAV Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
6.4.4 Latin America AAV Vector-Based Gene Therapy Drugs Major Customers
6.4.5 Latin America Market Trends and Opportunities
6.5 Middle East & Africa Market: Players, Segments, Downstream and Major Customers
6.5.1 Middle East & Africa AAV Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026)
6.5.2 Middle East & Africa Market Size by Type
6.5.2.1 Middle East & Africa AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026)
6.5.2.2 Middle East & Africa AAV Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
6.5.3 Middle East & Africa Market Size by Application
6.5.3.1 Middle East & Africa AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026)
6.5.3.2 Middle East & Africa AAV Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
6.5.4 Middle East & Africa AAV Vector-Based Gene Therapy Drugs Major Customers
6.5.5 Middle East & Africa Market Trends and Opportunities

7 Key Player Profiles
7.1 uniQure
7.1.1 uniQure Company Details
7.1.2 uniQure Business Overview
7.1.3 uniQure AAV Vector-Based Gene Therapy Drugs Introduction
7.1.4 uniQure Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
7.1.5 uniQure Recent Development
7.2 Spark Therapeutics
7.2.1 Spark Therapeutics Company Details
7.2.2 Spark Therapeutics Business Overview
7.2.3 Spark Therapeutics AAV Vector-Based Gene Therapy Drugs Introduction
7.2.4 Spark Therapeutics Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
7.2.5 Spark Therapeutics Recent Development
7.3 AveXis (Novartis)
7.3.1 AveXis (Novartis) Company Details
7.3.2 AveXis (Novartis) Business Overview
7.3.3 AveXis (Novartis) AAV Vector-Based Gene Therapy Drugs Introduction
7.3.4 AveXis (Novartis) Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
7.3.5 AveXis (Novartis) Recent Development
7.4 PTC Therapeutics
7.4.1 PTC Therapeutics Company Details
7.4.2 PTC Therapeutics Business Overview
7.4.3 PTC Therapeutics AAV Vector-Based Gene Therapy Drugs Introduction
7.4.4 PTC Therapeutics Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
7.4.5 PTC Therapeutics Recent Development
7.5 BioMarin
7.5.1 BioMarin Company Details
7.5.2 BioMarin Business Overview
7.5.3 BioMarin AAV Vector-Based Gene Therapy Drugs Introduction
7.5.4 BioMarin Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
7.5.5 BioMarin Recent Development
7.6 Sarepta Therapeutics
7.6.1 Sarepta Therapeutics Company Details
7.6.2 Sarepta Therapeutics Business Overview
7.6.3 Sarepta Therapeutics AAV Vector-Based Gene Therapy Drugs Introduction
7.6.4 Sarepta Therapeutics Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
7.6.5 Sarepta Therapeutics Recent Development
7.7 Roche
7.7.1 Roche Company Details
7.7.2 Roche Business Overview
7.7.3 Roche AAV Vector-Based Gene Therapy Drugs Introduction
7.7.4 Roche Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
7.7.5 Roche Recent Development
7.8 Pfizer
7.8.1 Pfizer Company Details
7.8.2 Pfizer Business Overview
7.8.3 Pfizer AAV Vector-Based Gene Therapy Drugs Introduction
7.8.4 Pfizer Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
7.8.5 Pfizer Recent Development

8 AAV Vector-Based Gene Therapy Drugs Market Dynamics
8.1 AAV Vector-Based Gene Therapy Drugs Industry Trends
8.2 AAV Vector-Based Gene Therapy Drugs Market Drivers
8.3 AAV Vector-Based Gene Therapy Drugs Market Challenges
8.4 AAV Vector-Based Gene Therapy Drugs Market Restraints

9 Research Findings and Conclusion

10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global AAV Vector-Based Gene Therapy Drugs Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
Table 2. Global AAV Vector-Based Gene Therapy Drugs Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
Table 3. Global Market AAV Vector-Based Gene Therapy Drugs Market Size (US$ Million) by Region:2021 vs 2025 vs 2032
Table 4. Global AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) Market Share by Region (2021-2026)
Table 5. Global AAV Vector-Based Gene Therapy Drugs Revenue Share by Region (2021-2026)
Table 6. Global AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) Forecast by Region (2027-2032)
Table 7. Global AAV Vector-Based Gene Therapy Drugs Revenue Share Forecast by Region (2027-2032)
Table 8. Global AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 9. Global AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Type (2021-2026)
Table 10. Global AAV Vector-Based Gene Therapy Drugs Forecasted Market Size by Type (2027-2032) & (US$ Million)
Table 11. Global AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Type (2027-2032)
Table 12. Representative Players of Each Type
Table 13. Global AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 14. Global AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Application (2021-2026)
Table 15. Global AAV Vector-Based Gene Therapy Drugs Forecasted Market Size by Application (2027-2032) & (US$ Million)
Table 16. Global AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Application (2027-2032)
Table 17. New Sources of Growth in AAV Vector-Based Gene Therapy Drugs Applications
Table 18. Global AAV Vector-Based Gene Therapy Drugs Revenue by Players (2021-2026) & (US$ Million)
Table 19. Global AAV Vector-Based Gene Therapy Drugs Market Share by Players (2021-2026)
Table 20. Global Top AAV Vector-Based Gene Therapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AAV Vector-Based Gene Therapy Drugs as of 2025)
Table 21. Ranking of Global Top AAV Vector-Based Gene Therapy Drugs Companies by Revenue (US$ Million) in 2025
Table 22. Global 5 Largest Players Market Share by AAV Vector-Based Gene Therapy Drugs Revenue (CR5 and HHI) & (2021-2026)
Table 23. Global Key Players of AAV Vector-Based Gene Therapy Drugs, Headquarters and Area Served
Table 24. Global Key Players of AAV Vector-Based Gene Therapy Drugs, Product and Application
Table 25. Global Key Players of AAV Vector-Based Gene Therapy Drugs, Date of Entry into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. North America AAV Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 28. North America AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Company (2021-2026)
Table 29. North America AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 30. North America AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 31. Europe AAV Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 32. Europe AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Company (2021-2026)
Table 33. Europe AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 34. Europe AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 35. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 36. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Company (2021-2026)
Table 37. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 38. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 39. Latin America AAV Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 40. Latin America AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Company (2021-2026)
Table 41. Latin America AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 42. Latin America AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 43. Middle East & Africa AAV Vector-Based Gene Therapy Drugs Revenue by Company (2021-2026) & (US$ Million)
Table 44. Middle East & Africa AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Company (2021-2026)
Table 45. Middle East & Africa AAV Vector-Based Gene Therapy Drugs Market Size by Type (2021-2026) & (US$ Million)
Table 46. Middle East & Africa AAV Vector-Based Gene Therapy Drugs Market Size by Application (2021-2026) & (US$ Million)
Table 47. uniQure Company Details
Table 48. uniQure Business Overview
Table 49. uniQure AAV Vector-Based Gene Therapy Drugs Product
Table 50. uniQure Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 51. uniQure Recent Development
Table 52. Spark Therapeutics Company Details
Table 53. Spark Therapeutics Business Overview
Table 54. Spark Therapeutics AAV Vector-Based Gene Therapy Drugs Product
Table 55. Spark Therapeutics Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 56. Spark Therapeutics Recent Development
Table 57. AveXis (Novartis) Company Details
Table 58. AveXis (Novartis) Business Overview
Table 59. AveXis (Novartis) AAV Vector-Based Gene Therapy Drugs Product
Table 60. AveXis (Novartis) Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 61. AveXis (Novartis) Recent Development
Table 62. PTC Therapeutics Company Details
Table 63. PTC Therapeutics Business Overview
Table 64. PTC Therapeutics AAV Vector-Based Gene Therapy Drugs Product
Table 65. PTC Therapeutics Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 66. PTC Therapeutics Recent Development
Table 67. BioMarin Company Details
Table 68. BioMarin Business Overview
Table 69. BioMarin AAV Vector-Based Gene Therapy Drugs Product
Table 70. BioMarin Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 71. BioMarin Recent Development
Table 72. Sarepta Therapeutics Company Details
Table 73. Sarepta Therapeutics Business Overview
Table 74. Sarepta Therapeutics AAV Vector-Based Gene Therapy Drugs Product
Table 75. Sarepta Therapeutics Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 76. Sarepta Therapeutics Recent Development
Table 77. Roche Company Details
Table 78. Roche Business Overview
Table 79. Roche AAV Vector-Based Gene Therapy Drugs Product
Table 80. Roche Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 81. Roche Recent Development
Table 82. Pfizer Company Details
Table 83. Pfizer Business Overview
Table 84. Pfizer AAV Vector-Based Gene Therapy Drugs Product
Table 85. Pfizer Revenue in AAV Vector-Based Gene Therapy Drugs Business (2021-2026) & (US$ Million)
Table 86. Pfizer Recent Development
Table 87. AAV Vector-Based Gene Therapy Drugs Market Trends
Table 88. AAV Vector-Based Gene Therapy Drugs Market Drivers
Table 89. AAV Vector-Based Gene Therapy Drugs Market Challenges
Table 90. AAV Vector-Based Gene Therapy Drugs Market Restraints
Table 91. Research Programs/Design for This Report
Table 92. Key Data Information from Secondary Sources
Table 93. Key Data Information from Primary Sources

List of Figures
Figure 1. AAV Vector-Based Gene Therapy Drugs Product Picture
Figure 2. Global AAV Vector-Based Gene Therapy Drugs Market Share by Type: 2025 vs 2032
Figure 3. AAV2 Vector Features
Figure 4. AAV5 Vector Features
Figure 5. Others Features
Figure 6. Global AAV Vector-Based Gene Therapy Drugs Market Share by Application: 2025 vs 2032
Figure 7. Hospital
Figure 8. Diagnostic and Testing Laboratories
Figure 9. Academic and Research Organizations
Figure 10. Others
Figure 11. AAV Vector-Based Gene Therapy Drugs Report Years Considered
Figure 12. Global AAV Vector-Based Gene Therapy Drugs Market Size (US$ Million), Year-over-Year: 2021-2032
Figure 13. Global AAV Vector-Based Gene Therapy Drugs Market Size, (US$ Million), 2021 vs 2025 vs 2032
Figure 14. Global AAV Vector-Based Gene Therapy Drugs Market Share by Revenue, by Region: 2021 vs 2025
Figure 15. North America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 16. Europe AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 17. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 18. Latin America AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 19. Middle East & Africa AAV Vector-Based Gene Therapy Drugs Revenue (US$ Million) Growth Rate (2021-2032)
Figure 20. Global AAV Vector-Based Gene Therapy Drugs Market Share by Players in 2025
Figure 21. Global Top AAV Vector-Based Gene Therapy Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in AAV Vector-Based Gene Therapy Drugs as of 2025)
Figure 22. The Top 10 and 5 Players Market Share by AAV Vector-Based Gene Therapy Drugs Revenue in 2025
Figure 23. North America AAV Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
Figure 24. North America AAV Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
Figure 25. Europe AAV Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
Figure 26. Europe AAV Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
Figure 27. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
Figure 28. Asia-Pacific AAV Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
Figure 29. Latin America AAV Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
Figure 30. Latin America AAV Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
Figure 31. Middle East & Africa AAV Vector-Based Gene Therapy Drugs Market Share by Type (2021-2026)
Figure 32. Middle East & Africa AAV Vector-Based Gene Therapy Drugs Market Share by Application (2021-2026)
Figure 33. uniQure Revenue Growth Rate in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 34. Spark Therapeutics Revenue Growth Rate in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 35. AveXis (Novartis) Revenue Growth Rate in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 36. PTC Therapeutics Revenue Growth Rate in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 37. BioMarin Revenue Growth Rate in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 38. Sarepta Therapeutics Revenue Growth Rate in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 39. Roche Revenue Growth Rate in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 40. Pfizer Revenue Growth Rate in AAV Vector-Based Gene Therapy Drugs Business (2021-2026)
Figure 41. Bottom-up and Top-down Approaches for This Report
Figure 42. Data Triangulation
Figure 43. Key Executives Interviewed